CarboplatinTaxoidsPaclitaxelAntineoplastic Combined Chemotherapy ProtocolsDrug Administration ScheduleAntineoplastic Agents, PhytogenicAntineoplastic AgentsLung NeoplasmsCisplatinTreatment OutcomeOvarian NeoplasmsCarcinoma, Non-Small-Cell LungDeoxycytidineMaximum Tolerated DoseInfusions, IntravenousPlatinumNeutropeniaEtoposideIfosfamideDisease-Free SurvivalCombined Modality TherapyArea Under CurveLeukopeniaDose-Response Relationship, DrugThrombocytopeniaOrganoplatinum CompoundsSurvival AnalysisNeoplasm StagingSurvival RateEstramustineFallopian Tube NeoplasmsBreast NeoplasmsVinblastineNeoplasm MetastasisDrug Resistance, NeoplasmHematologic DiseasesNeoplasmsRetinal NeoplasmsEpirubicinDoxorubicinCyclophosphamideFluorouracilProstatic NeoplasmsThiotepaAntibodies, Monoclonal, HumanizedNeoplasm Recurrence, LocalPeritoneal NeoplasmsRetinoblastomaNeoadjuvant TherapyAdenocarcinomaAmifostineAstheniaAlopeciaChemotherapy, AdjuvantTopotecanDrug SynergismCarcinoma, Small CellNauseaDrug HypersensitivityPlatinum CompoundsCarcinomaDrug EvaluationFeasibility StudiesDisease ProgressionCell Line, TumorOxonic AcidFolic Acid TransportersGuanineSalvage TherapySeminomaUrologic NeoplasmsGranulocyte Colony-Stimulating FactorVomitingHead and Neck NeoplasmsKaplan-Meier EstimateRemission InductionGlutamatesIsocoumarinsMitoxantroneGerminomaBridged CompoundsCarcinoma, Squamous CellDrug Screening Assays, AntitumorTesticular NeoplasmsCamptothecinTegafurNeoplasms, Glandular and EpithelialQuinazolinesXenograft Model Antitumor AssaysNeoplasms, Germ Cell and EmbryonalNeoplasms, Unknown PrimaryProstate-Specific AntigenEarly Termination of Clinical TrialsBone NeoplasmsOrchiectomyAntibodies, MonoclonalDose FractionationMesnaAdministration, OralAnthracyclines